CCM vs. XGN, TOI, PIII, BNR, ENZ, BRTX, MRAI, MGRX, OPGN, and KDLY
Should you be buying Concord Medical Services stock or one of its competitors? The main competitors of Concord Medical Services include Exagen (XGN), Oncology Institute (TOI), P3 Health Partners (PIII), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), BioRestorative Therapies (BRTX), Marpai (MRAI), Mangoceuticals (MGRX), OpGen (OPGN), and Kindly MD (KDLY). These companies are all part of the "healthcare" industry.
Concord Medical Services vs.
Exagen (NASDAQ:XGN) and Concord Medical Services (NYSE:CCM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.
75.3% of Exagen shares are held by institutional investors. 26.1% of Exagen shares are held by insiders. Comparatively, 46.5% of Concord Medical Services shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Concord Medical Services has a net margin of 0.00% compared to Exagen's net margin of -30.36%. Concord Medical Services' return on equity of 0.00% beat Exagen's return on equity.
Exagen currently has a consensus price target of $7.50, indicating a potential upside of 109.50%. Given Exagen's stronger consensus rating and higher probable upside, research analysts clearly believe Exagen is more favorable than Concord Medical Services.
Exagen has higher earnings, but lower revenue than Concord Medical Services.
In the previous week, Concord Medical Services had 2 more articles in the media than Exagen. MarketBeat recorded 2 mentions for Concord Medical Services and 0 mentions for Exagen. Exagen's average media sentiment score of 0.00 equaled Concord Medical Services'average media sentiment score.
Concord Medical Services received 174 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 60.24% of users gave Concord Medical Services an outperform vote while only 57.50% of users gave Exagen an outperform vote.
Exagen has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Concord Medical Services has a beta of -0.37, indicating that its share price is 137% less volatile than the S&P 500.
Summary
Concord Medical Services beats Exagen on 8 of the 15 factors compared between the two stocks.
Get Concord Medical Services News Delivered to You Automatically
Sign up to receive the latest news and ratings for CCM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Concord Medical Services Competitors List
Related Companies and Tools
This page (NYSE:CCM) was last updated on 2/22/2025 by MarketBeat.com Staff
